Table 2.
Management of 147 Patients With Cryptococcosis by Receipt of Infectious Disease Consultation, 2002–2015
| Treatment | ID Consult (n = 100) |
No ID Consult (n = 47) |
P Value | Total Cohort (N = 147) |
|---|---|---|---|---|
| LP performed when indicated | 79/92 (86) | 12/37 (33) | <.001 | 91/129 (71) |
| LP performed when not indicated | 2/8 (25) | 3/10 (30) | .81 | 5/18 (27.8) |
| No. of LPs performed among those who had at least 1, median (range) | 2 (1–18) | 1 (1–3) | .048 | 2 (1–18) |
| Neurosurgical intervention for ICP managementa | 8 (8) | 0 (0) | .042 | 8 (5.4) |
| AmB administered when indicated | 81/93 (87) | 11/45 (24) | <.001 | 76/138 (55) |
| Duration of AmB therapy when indicated, d, median (IQR) | 14 (16) | 11 (9) | .050 | 14 (14.5) |
| 5-FC administered when indicated | 53/93 (57) | 7/45 (16) | <.001 | 60/138 (44) |
| Duration of 5-FC therapy when indicated, d, median (IQR) | 7.5 (13) | 1 (1) | <.001 | 4 (14) |
Data are presented as No. (%) unless otherwise indicated. Among the patients without an indication for AmB and 5-FC, none received either AmB or 5-FC.
Abbreviations: 5-FC, flucytosine; AmB, amphotericin B; ICP, intracranial pressure; ID, infectious disease; IQR, interquartile range; LP, lumbar puncture.
a
Includes ventriculoperitoneal shuts and external drains.